Molecules of parasites as immunomodulatory drugs

• Published in: Current topics in medicinal chemistry Vol. 4; no. 5; p. 539
• Main Authors: Imai, Shinjiro, Fujita, Koichiro
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2004
• Subjects: Adjuvants, Immunologic - therapeutic use; Animals; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - therapy; Disease Models, Animal; Helminth Proteins - therapeutic use; Parasitic Diseases - immunology; Parasitic Diseases - therapy; Rats; Th1 Cells - immunology; Th2 Cells - immunology
• ISSN: 1568-0266
• DOI: 10.2174/1568026043451285

Parasite molecules offer unique advantages for the treatment of immunologicical disorders, and several candidate molecules have been shown to be effective. In our studies, it was shown that a factor inducing immunoglobulin E from filarial nematode parasites was suppressive in animal models of immunological disorders such as allergy and insulin dependent diabetes mellitus (IDDM). The Th1/Th2 paradigm of CD4+ T helper cell subsets can provide the basis for the development of new types of drugs and of novel strategies for the treatment of allergic and autoimmune disorders by parasite molecules. In our experimental system, parasite molecules from a filarial nematode parasite led to the down-regulation of the allergic reaction in animal models. In the majority of hosts, infection with helminths is associated with markedly reduced cellular immune reactions and polarization of T cell responses to Th2 and Th3 types. Some studies have suggested that the stimulation of host immunoregulatory networks with parasite molecules leading to the synthesis of anti-inflammatory cytokines (interleukin10, transforming growth factor-beta (TGF-beta and others) can provide new therapy for immunological disorders. It is known that parasites produce some types of molecule that mimic host molecules such as CD40 ligand, TGF-beta and macrophage migration inhibitory factor. These molecules are also candidates for medicinal agents. This review describes many of the latest possibilities in this field and shows how they can be best put to use for the development of medicinal agents, molecular target identification, and for prioritization.